CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
CDT Equity Inc. announced an updated strategic positioning as a multi-pathway value creation business combining pharmaceutical assets licensed from AstraZeneca, proprietary solid-form intellectual property, and AI-driven indication discovery through its stake in Sarborg Limited. The company focuses on capital-efficient, out-licensing models leverag…